Page last updated: 2024-08-17

quinoxalines and Lung Adenocarcinoma

quinoxalines has been researched along with Lung Adenocarcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ji, J; Li, X; Meng, X; Shu, H; Wang, K; Wang, X; Xie, G; Zhao, H; Zhong, H; Zhu, X	1

Other Studies

1 other study(ies) available for quinoxalines and Lung Adenocarcinoma

Article	Year
Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor. Molecules (Basel, Switzerland), 2022, Oct-09, Volume: 27, Issue:19 Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Carcinogenesis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines	2022

Article

Year

Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor.

Molecules (Basel, Switzerland), 2022, Oct-09, Volume: 27, Issue:19

Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Carcinogenesis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines

2022